Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 5Recruiting 3Terminated 2Active not recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2Gynecologic 2Gastrointestinal 2Thoracic 1Genitourinary 1

Conditions

Neoplasms 2Pancreatic Neoplasms 1Colorectal Neoplasms 1

Interventions

Fluorouracil 145Gemcitabine 141Oxaliplatin 135Capecitabine 133Leucovorin 107Irinotecan 99Bevacizumab 92Cetuximab 69Cisplatin 67pembrolizumab 61Radiotherapy 60Nivolumab 41130-nm albumin-bound paclitaxel 41Sorafenib 39Docetaxel 34Albumin-Bound Paclitaxel 31Radiosurgery 28Paclitaxel 27Surgical Procedures, Operative 25regorafenib 24Erlotinib Hydrochloride 23Panitumumab 22Cyclophosphamide 21Celecoxib 20Trastuzumab 19Radiation 18Neoadjuvant Therapy 18IFL protocol 18atezolizumab 17Carboplatin 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × budigalimab × Gastrointestinal × Clear all
NCT04807972 2025-01-07

Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of ABBV-927 is Administered in Combination With IV Modified FOLFIRINOX (mFFX) With or Without IV Budigalimab Compared to mFFX in Adult Participants With Untreated Pancreatic Cancer Metastasis

AbbVie

Phase 1 Terminated
40 enrolled
Gastrointestinal

Neoplasms, Pancreatic Neoplasms

NCT03035279 2020-02-20

A Study of SC-006 and in Combination With ABBV-181 in Subjects With Advanced Colorectal Cancer

AbbVie

Phase 1 Terminated
29 enrolled
Gastrointestinal

Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡